The PE Ratio as of December 2024 (TTM) for Akari Therapeutics, Plc (AKTX) is -0.37

According to Akari Therapeutics, Plc’s latest financial reports and current stock price. The company's current PE Ratio is -0.37. This represents a change of -74.33% compared to the average of -1.44 of the last 4 quarters.

Akari Therapeutics, Plc (AKTX) Historical PE Ratio (quarterly & annually)

How has AKTX PE Ratio performed in the past?

The mean historical PE Ratio of Akari Therapeutics, Plc over the last ten years is -30.93. The current -0.37 PE Ratio has changed 19.62% with respect to the historical average. Over the past ten years (40 quarters), AKTX's PE Ratio was at its highest in in the September 2020 quarter at 10.22. The PE Ratio was at its lowest in in the September 2021 quarter at -265.69.

Akari Therapeutics, Plc (AKTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Akari Therapeutics, Plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Akari Therapeutics, Plc (AKTX) Average PE Ratio

How has AKTX PE Ratio performed in the past?

The current PE Ratio of Akari Therapeutics, Plc (AKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Akari Therapeutics, Plc (AKTX) PE Ratio vs. Peers

How is AKTX’s PE Ratio compared to its peers?

Akari Therapeutics, Plc’s PE Ratio is greater than Armata Pharmaceuticals, Inc. (-1.70), greater than Anebulo Pharmaceuticals, Inc. (-4.09), less than Scopus BioPharma Inc. (-0.00), less than Processa Pharmaceuticals, Inc. (-0.24), less than Salarius Pharmaceuticals, Inc. (0), greater than Axcella Health Inc. (-0.40), greater than Magenta Therapeutics, Inc. (-3.07), less than Histogen Inc. (-0.15), less than Pulmatrix, Inc. (-0.01), greater than Capricor Therapeutics, Inc. (-2.18), greater than Diffusion Pharmaceuticals Inc. (-13.71), greater than Soleno Therapeutics, Inc. (-1.61), greater than Oncorus, Inc. (-14.35), less than Sonnet BioTherapeutics Holdings, Inc. (-0.04), less than Landos Biopharma, Inc. (-0.18), greater than null (-5.74),

Build a custom stock screener for Akari Therapeutics, Plc (AKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akari Therapeutics, Plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akari Therapeutics, Plc (AKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akari Therapeutics, Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.